Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 5 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

Shear failure image after 8 freeze‒thaw cycles. by Ruihong Wang (1932328)

“…The results show that the shear strength of a root–soil composite increases with increasing confining pressure and VC and decreases with increasing number of freeze‒thaw cycles. …”

Supplementary figure 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma by Douglas W. Sborov (10760514)

Drug combinations with trametinib decrease the colony-forming ability of GIST cell lines. by Anu Gupta (467592)

Supplementary Figures 1-5 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance by Lina Y. Dimberg (15077439)

Supplemental Figure 6 from Acute Tumor Lactate Perturbations as a Biomarker of Genotoxic Stress: Development of a Biochemical Model by Vlad C. Sandulache (9394245)

Supplemental Movie 1 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin by Samriddhi Shukla (321547)

Supplemental Movie 3 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin by Samriddhi Shukla (321547)

Supplemental Movie 2 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin by Samriddhi Shukla (321547)

Supplemental Movie 4 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin by Samriddhi Shukla (321547)

Supplemental Movie 6 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin by Samriddhi Shukla (321547)

Supplemental Movie 5 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin by Samriddhi Shukla (321547)